Typical of studies of this type and phase, our analyses were conducted in only a small number of patients, and among only a selection of tumours rather than across the whole tumour burden which may mean that the heterogeneity of PSMA expression expected in a real-world population of patients with prostate cancer [7, 8, 9] may not be accurately represented. The gene discussed is FOLH1; the disease is prostate carcinoma.